WHO ICTRP trial
Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in…
EUCTR2009-009256-20-NL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-009256-20-NL |
|---|---|
| Public title | Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL |
| Scientific title | Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL |
| Primary sponsor | GlaxoSmithKline Research and Development Limited |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Estonia;Greece;Finland;Spain;Ireland;Austria;United Kingdom;Czech Republic;Hungary;Belgium;Poland;Denmark;Netherlands;Germany;Sweden |
| Conditions | Diffuse Large B-Cell Lymphoma (DLBCL) |
| Interventions | Product Name: ofatumumab Product Code: GSK1841157 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Ofatumumab Current Sponsor code: GSK1841157 Concentration unit: mg/ml milligram(s)/millilitre Concentration… |
| Registration date | Mar 9, 2009 |
| Target size | 380 |
| Secondary IDs | OMB110928 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: